SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-044805
Filing Date
2024-05-17
Accepted
2024-05-17 17:09:37
Documents
70
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0205616-10q_cero.htm   iXBRL 10-Q 749572
2 CERTIFICATION ea020561601ex31-1_cero.htm EX-31.1 11835
3 CERTIFICATION ea020561601ex31-2_cero.htm EX-31.2 11853
4 CERTIFICATION ea020561601ex32-1_cero.htm EX-32.1 4565
5 CERTIFICATION ea020561601ex32-2_cero.htm EX-32.2 4555
  Complete submission text file 0001213900-24-044805.txt   5175381

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cero-20240331.xsd EX-101.SCH 60902
7 XBRL CALCULATION FILE cero-20240331_cal.xml EX-101.CAL 31440
8 XBRL DEFINITION FILE cero-20240331_def.xml EX-101.DEF 279386
9 XBRL LABEL FILE cero-20240331_lab.xml EX-101.LAB 466811
10 XBRL PRESENTATION FILE cero-20240331_pre.xml EX-101.PRE 274004
74 EXTRACTED XBRL INSTANCE DOCUMENT ea0205616-10q_cero_htm.xml XML 600966
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

IRS No.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40877 | Film No.: 24961241
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)